fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Showing products 1–24 of 62. More products

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Metformin HCL

12 general benefit · 12 not a benefit

Auro-Metformin · DIN 02438275 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Metformin · DIN 02438275 Manufacturer: Auro Pharma Inc.; listing date 2015-07-29 Health Canada: Marketed since 2017-02-22 · brand AURO-METFORMIN · ATC A10BA02 METFORMIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Metformin: Formulary list price $0.02 per unit (the source does not state the unit; exact figure $0.0247). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02438275)

Source record
DIN 02438275: Auro-Metformin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002008; group id 750; item number 1837; lccId None; manufacturer id AUR Source form: Tab; strength: 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0247; ministry $0.0247 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02438275 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92264
Interchangeable products
Apo-Metformin · DIN 02167786 · $0.0247 Glucophage · DIN 02099233 · $0.0247 Jamp-Metformin · DIN 02380196 · $0.0247 M-Metformin · DIN 02547767 · $0.0247 Mar-Metformin · DIN 02378620 · $0.0247 Metformin · DIN 02353377 · $0.0247 Metformin FC · DIN 02385341 · $0.0247 Mint-Metformin · DIN 02388766 · $0.0247 NRA-Metformin · DIN 02536439 · $0.0247 Novo-Metformin · DIN 02045710 · $0.0247 PMS-Metformin · DIN 02223562 · $0.0247 PMSC-Metformin · DIN 02520303 · $0.0247 PRZ-Metformin · DIN 02531895 · $0.0247 Ran-Metformin · DIN 02269031 · $0.0247 Ratio-Metformin · DIN 02242974 · $0.0247 Sandoz Metformin FC · DIN 02246820 · $0.0247 Septa-Metformin · DIN 02379767 · $0.0247 Teva-Metformin · DIN 02257726 · $0.0247
Shortage status: resolved shortage (ended April 16, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02438275
Shortage record checked October 6, 2026

Glucophage · DIN 02099233 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Savings card: RxHelp ONE lists GLUCOPHAGE (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Glucophage · DIN 02099233 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Health Canada: Marketed since 2007-10-09 · brand GLUCOPHAGE · ATC A10BA02 METFORMIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG · company Sanofi-aventis canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02099233)

Source record
DIN 02099233: Glucophage Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002008; group id 750; item number 1837; lccId None; manufacturer id SAV Source form: Tab; strength: 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.2938; ministry $0.0247 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02099233 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17104
Interchangeable products
Apo-Metformin · DIN 02167786 · $0.0247 Auro-Metformin · DIN 02438275 · $0.0247 Jamp-Metformin · DIN 02380196 · $0.0247 M-Metformin · DIN 02547767 · $0.0247 Mar-Metformin · DIN 02378620 · $0.0247 Metformin · DIN 02353377 · $0.0247 Metformin FC · DIN 02385341 · $0.0247 Mint-Metformin · DIN 02388766 · $0.0247 NRA-Metformin · DIN 02536439 · $0.0247 Novo-Metformin · DIN 02045710 · $0.0247 PMS-Metformin · DIN 02223562 · $0.0247 PMSC-Metformin · DIN 02520303 · $0.0247 PRZ-Metformin · DIN 02531895 · $0.0247 Ran-Metformin · DIN 02269031 · $0.0247 Ratio-Metformin · DIN 02242974 · $0.0247 Sandoz Metformin FC · DIN 02246820 · $0.0247 Septa-Metformin · DIN 02379767 · $0.0247 Teva-Metformin · DIN 02257726 · $0.0247
Shortage status: resolved shortage (ended August 31, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02099233
Shortage record checked October 6, 2026

Jamp-Metformin · DIN 02380196 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Metformin · DIN 02380196 Manufacturer: Jamp Pharma Corporation; listing date 2012-08-27 Health Canada: Marketed since 2019-09-24 · brand JAMP METFORMIN · ATC A10BA02 METFORMIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp-Metformin: Formulary list price $0.02 per unit (the source does not state the unit; exact figure $0.0247). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02380196)

Source record
DIN 02380196: Jamp-Metformin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002008; group id 750; item number 1837; lccId None; manufacturer id JPC Source form: Tab; strength: 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0247; ministry $0.0247 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02380196 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86602
Interchangeable products
Apo-Metformin · DIN 02167786 · $0.0247 Auro-Metformin · DIN 02438275 · $0.0247 Glucophage · DIN 02099233 · $0.0247 M-Metformin · DIN 02547767 · $0.0247 Mar-Metformin · DIN 02378620 · $0.0247 Metformin · DIN 02353377 · $0.0247 Metformin FC · DIN 02385341 · $0.0247 Mint-Metformin · DIN 02388766 · $0.0247 NRA-Metformin · DIN 02536439 · $0.0247 Novo-Metformin · DIN 02045710 · $0.0247 PMS-Metformin · DIN 02223562 · $0.0247 PMSC-Metformin · DIN 02520303 · $0.0247 PRZ-Metformin · DIN 02531895 · $0.0247 Ran-Metformin · DIN 02269031 · $0.0247 Ratio-Metformin · DIN 02242974 · $0.0247 Sandoz Metformin FC · DIN 02246820 · $0.0247 Septa-Metformin · DIN 02379767 · $0.0247 Teva-Metformin · DIN 02257726 · $0.0247
Shortage status: resolved shortage (ended March 17, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02380196
Shortage record checked October 6, 2026

M-Metformin · DIN 02547767 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Metformin · DIN 02547767 Manufacturer: Mantra Pharma Inc.; listing date 2025-01-31 Health Canada: Marketed since 2024-11-14 · brand M-METFORMIN · ATC A10BA02 METFORMIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

M-Metformin: Formulary list price $0.02 per unit (the source does not state the unit; exact figure $0.0247). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02547767)

Source record
DIN 02547767: M-Metformin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002008; group id 750; item number 1837; lccId None; manufacturer id MAT Source form: Tab; strength: 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0247; ministry $0.0247 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02547767 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103669
Interchangeable products
Apo-Metformin · DIN 02167786 · $0.0247 Auro-Metformin · DIN 02438275 · $0.0247 Glucophage · DIN 02099233 · $0.0247 Jamp-Metformin · DIN 02380196 · $0.0247 Mar-Metformin · DIN 02378620 · $0.0247 Metformin · DIN 02353377 · $0.0247 Metformin FC · DIN 02385341 · $0.0247 Mint-Metformin · DIN 02388766 · $0.0247 NRA-Metformin · DIN 02536439 · $0.0247 Novo-Metformin · DIN 02045710 · $0.0247 PMS-Metformin · DIN 02223562 · $0.0247 PMSC-Metformin · DIN 02520303 · $0.0247 PRZ-Metformin · DIN 02531895 · $0.0247 Ran-Metformin · DIN 02269031 · $0.0247 Ratio-Metformin · DIN 02242974 · $0.0247 Sandoz Metformin FC · DIN 02246820 · $0.0247 Septa-Metformin · DIN 02379767 · $0.0247 Teva-Metformin · DIN 02257726 · $0.0247
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02547767
Shortage record checked October 6, 2026

Mar-Metformin · DIN 02378620 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Metformin · DIN 02378620 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2012-07-27 Health Canada: Marketed since 2023-06-26 · brand MAR-METFORMIN · ATC A10BA02 METFORMIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mar-Metformin: Formulary list price $0.02 per unit (the source does not state the unit; exact figure $0.0247). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02378620)

Source record
DIN 02378620: Mar-Metformin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002008; group id 750; item number 1837; lccId None; manufacturer id MAR Source form: Tab; strength: 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0247; ministry $0.0247 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02378620 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86441
Interchangeable products
Apo-Metformin · DIN 02167786 · $0.0247 Auro-Metformin · DIN 02438275 · $0.0247 Glucophage · DIN 02099233 · $0.0247 Jamp-Metformin · DIN 02380196 · $0.0247 M-Metformin · DIN 02547767 · $0.0247 Metformin · DIN 02353377 · $0.0247 Metformin FC · DIN 02385341 · $0.0247 Mint-Metformin · DIN 02388766 · $0.0247 NRA-Metformin · DIN 02536439 · $0.0247 Novo-Metformin · DIN 02045710 · $0.0247 PMS-Metformin · DIN 02223562 · $0.0247 PMSC-Metformin · DIN 02520303 · $0.0247 PRZ-Metformin · DIN 02531895 · $0.0247 Ran-Metformin · DIN 02269031 · $0.0247 Ratio-Metformin · DIN 02242974 · $0.0247 Sandoz Metformin FC · DIN 02246820 · $0.0247 Septa-Metformin · DIN 02379767 · $0.0247 Teva-Metformin · DIN 02257726 · $0.0247
Shortage status: discontinued (November 30, 2017, reported by MARCAN PHARMACEUTICALS INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02378620
Shortage record checked October 6, 2026

Metformin · DIN 02353377 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Metformin · DIN 02353377 Manufacturer: Sanis Health Inc.; listing date 2011-08-04 Health Canada: Marketed since 2019-05-30 · brand METFORMIN · ATC A10BA02 METFORMIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Metformin: Formulary list price $0.02 per unit (the source does not state the unit; exact figure $0.0247). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02353377)

Source record
DIN 02353377: Metformin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002008; group id 750; item number 1837; lccId None; manufacturer id SAI Source form: Tab; strength: 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0247; ministry $0.0247 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02353377 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83857
Interchangeable products
Apo-Metformin · DIN 02167786 · $0.0247 Auro-Metformin · DIN 02438275 · $0.0247 Glucophage · DIN 02099233 · $0.0247 Jamp-Metformin · DIN 02380196 · $0.0247 M-Metformin · DIN 02547767 · $0.0247 Mar-Metformin · DIN 02378620 · $0.0247 Metformin FC · DIN 02385341 · $0.0247 Mint-Metformin · DIN 02388766 · $0.0247 NRA-Metformin · DIN 02536439 · $0.0247 Novo-Metformin · DIN 02045710 · $0.0247 PMS-Metformin · DIN 02223562 · $0.0247 PMSC-Metformin · DIN 02520303 · $0.0247 PRZ-Metformin · DIN 02531895 · $0.0247 Ran-Metformin · DIN 02269031 · $0.0247 Ratio-Metformin · DIN 02242974 · $0.0247 Sandoz Metformin FC · DIN 02246820 · $0.0247 Septa-Metformin · DIN 02379767 · $0.0247 Teva-Metformin · DIN 02257726 · $0.0247
Shortage status: resolved shortage (ended July 3, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02353377
Shortage record checked October 6, 2026

Metformin FC · DIN 02385341 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Metformin FC · DIN 02385341 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-11-30 Health Canada: Marketed since 2026-05-20 · brand METFORMIN · ATC A10BA02 METFORMIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Metformin FC: Formulary list price $0.02 per unit (the source does not state the unit; exact figure $0.0247). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02385341)

Source record
DIN 02385341: Metformin FC Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002008; group id 750; item number 1837; lccId None; manufacturer id SIV Source form: Tab; strength: 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0247; ministry $0.0247 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02385341 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87098
Interchangeable products
Apo-Metformin · DIN 02167786 · $0.0247 Auro-Metformin · DIN 02438275 · $0.0247 Glucophage · DIN 02099233 · $0.0247 Jamp-Metformin · DIN 02380196 · $0.0247 M-Metformin · DIN 02547767 · $0.0247 Mar-Metformin · DIN 02378620 · $0.0247 Metformin · DIN 02353377 · $0.0247 Mint-Metformin · DIN 02388766 · $0.0247 NRA-Metformin · DIN 02536439 · $0.0247 Novo-Metformin · DIN 02045710 · $0.0247 PMS-Metformin · DIN 02223562 · $0.0247 PMSC-Metformin · DIN 02520303 · $0.0247 PRZ-Metformin · DIN 02531895 · $0.0247 Ran-Metformin · DIN 02269031 · $0.0247 Ratio-Metformin · DIN 02242974 · $0.0247 Sandoz Metformin FC · DIN 02246820 · $0.0247 Septa-Metformin · DIN 02379767 · $0.0247 Teva-Metformin · DIN 02257726 · $0.0247
Shortage status: resolved shortage (ended April 28, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02385341
Shortage record checked October 6, 2026

Mint-Metformin · DIN 02388766 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Metformin · DIN 02388766 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2012-09-28 Health Canada: Marketed since 2023-11-16 · brand MINT-METFORMIN · ATC A10BA02 METFORMIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mint-Metformin: Formulary list price $0.02 per unit (the source does not state the unit; exact figure $0.0247). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02388766)

Source record
DIN 02388766: Mint-Metformin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002008; group id 750; item number 1837; lccId None; manufacturer id MIN Source form: Tab; strength: 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0247; ministry $0.0247 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02388766 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87428
Interchangeable products
Apo-Metformin · DIN 02167786 · $0.0247 Auro-Metformin · DIN 02438275 · $0.0247 Glucophage · DIN 02099233 · $0.0247 Jamp-Metformin · DIN 02380196 · $0.0247 M-Metformin · DIN 02547767 · $0.0247 Mar-Metformin · DIN 02378620 · $0.0247 Metformin · DIN 02353377 · $0.0247 Metformin FC · DIN 02385341 · $0.0247 NRA-Metformin · DIN 02536439 · $0.0247 Novo-Metformin · DIN 02045710 · $0.0247 PMS-Metformin · DIN 02223562 · $0.0247 PMSC-Metformin · DIN 02520303 · $0.0247 PRZ-Metformin · DIN 02531895 · $0.0247 Ran-Metformin · DIN 02269031 · $0.0247 Ratio-Metformin · DIN 02242974 · $0.0247 Sandoz Metformin FC · DIN 02246820 · $0.0247 Septa-Metformin · DIN 02379767 · $0.0247 Teva-Metformin · DIN 02257726 · $0.0247
Shortage status: resolved shortage (ended November 16, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02388766
Shortage record checked October 6, 2026

NRA-Metformin · DIN 02536439 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Metformin · DIN 02536439 Manufacturer: Nora Pharma; listing date 2023-10-31 Health Canada: Marketed since 2023-08-03 · brand NRA-METFORMIN · ATC A10BA02 METFORMIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

NRA-Metformin: Formulary list price $0.02 per unit (the source does not state the unit; exact figure $0.0247). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02536439)

Source record
DIN 02536439: NRA-Metformin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002008; group id 750; item number 1837; lccId None; manufacturer id NRA Source form: Tab; strength: 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0247; ministry $0.0247 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02536439 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102521
Interchangeable products
Apo-Metformin · DIN 02167786 · $0.0247 Auro-Metformin · DIN 02438275 · $0.0247 Glucophage · DIN 02099233 · $0.0247 Jamp-Metformin · DIN 02380196 · $0.0247 M-Metformin · DIN 02547767 · $0.0247 Mar-Metformin · DIN 02378620 · $0.0247 Metformin · DIN 02353377 · $0.0247 Metformin FC · DIN 02385341 · $0.0247 Mint-Metformin · DIN 02388766 · $0.0247 Novo-Metformin · DIN 02045710 · $0.0247 PMS-Metformin · DIN 02223562 · $0.0247 PMSC-Metformin · DIN 02520303 · $0.0247 PRZ-Metformin · DIN 02531895 · $0.0247 Ran-Metformin · DIN 02269031 · $0.0247 Ratio-Metformin · DIN 02242974 · $0.0247 Sandoz Metformin FC · DIN 02246820 · $0.0247 Septa-Metformin · DIN 02379767 · $0.0247 Teva-Metformin · DIN 02257726 · $0.0247
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02536439
Shortage record checked October 6, 2026

PRZ-Metformin · DIN 02531895 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PRZ-Metformin · DIN 02531895 Manufacturer: Pharmaris Canada Inc.; listing date 2023-07-31 Health Canada: Marketed since 2023-04-14 · brand PRZ-METFORMIN · ATC A10BA02 METFORMIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG · company Pharmaris canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PRZ-Metformin: Formulary list price $0.02 per unit (the source does not state the unit; exact figure $0.0247). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02531895)

Source record
DIN 02531895: PRZ-Metformin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002008; group id 750; item number 1837; lccId None; manufacturer id PRZ Source form: Tab; strength: 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0247; ministry $0.0247 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02531895 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102098
Interchangeable products
Apo-Metformin · DIN 02167786 · $0.0247 Auro-Metformin · DIN 02438275 · $0.0247 Glucophage · DIN 02099233 · $0.0247 Jamp-Metformin · DIN 02380196 · $0.0247 M-Metformin · DIN 02547767 · $0.0247 Mar-Metformin · DIN 02378620 · $0.0247 Metformin · DIN 02353377 · $0.0247 Metformin FC · DIN 02385341 · $0.0247 Mint-Metformin · DIN 02388766 · $0.0247 NRA-Metformin · DIN 02536439 · $0.0247 Novo-Metformin · DIN 02045710 · $0.0247 PMS-Metformin · DIN 02223562 · $0.0247 PMSC-Metformin · DIN 02520303 · $0.0247 Ran-Metformin · DIN 02269031 · $0.0247 Ratio-Metformin · DIN 02242974 · $0.0247 Sandoz Metformin FC · DIN 02246820 · $0.0247 Septa-Metformin · DIN 02379767 · $0.0247 Teva-Metformin · DIN 02257726 · $0.0247
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02531895
Shortage record checked October 6, 2026

Sandoz Metformin FC · DIN 02246820 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Metformin FC · DIN 02246820 Manufacturer: Sandoz Canada Inc.; listing date 2003-09-04 Health Canada: Marketed since 2006-01-12 · brand SANDOZ METFORMIN FC · ATC A10BA02 METFORMIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Metformin FC: Formulary list price $0.02 per unit (the source does not state the unit; exact figure $0.0247). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02246820)

Source record
DIN 02246820: Sandoz Metformin FC Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002008; group id 750; item number 1837; lccId None; manufacturer id SDZ Source form: Tab; strength: 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0247; ministry $0.0247 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02246820 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71020
Interchangeable products
Apo-Metformin · DIN 02167786 · $0.0247 Auro-Metformin · DIN 02438275 · $0.0247 Glucophage · DIN 02099233 · $0.0247 Jamp-Metformin · DIN 02380196 · $0.0247 M-Metformin · DIN 02547767 · $0.0247 Mar-Metformin · DIN 02378620 · $0.0247 Metformin · DIN 02353377 · $0.0247 Metformin FC · DIN 02385341 · $0.0247 Mint-Metformin · DIN 02388766 · $0.0247 NRA-Metformin · DIN 02536439 · $0.0247 Novo-Metformin · DIN 02045710 · $0.0247 PMS-Metformin · DIN 02223562 · $0.0247 PMSC-Metformin · DIN 02520303 · $0.0247 PRZ-Metformin · DIN 02531895 · $0.0247 Ran-Metformin · DIN 02269031 · $0.0247 Ratio-Metformin · DIN 02242974 · $0.0247 Septa-Metformin · DIN 02379767 · $0.0247 Teva-Metformin · DIN 02257726 · $0.0247
Shortage status: shortage reported ended October 5, 2026 (report last updated October 5, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246820
Shortage record checked October 6, 2026

Teva-Metformin · DIN 02257726 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Metformin · DIN 02257726 Manufacturer: Teva Canada Limited; listing date 2004-12-21 Health Canada: Marketed since 2023-06-15 · brand TEVA-METFORMIN · ATC A10BA02 METFORMIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Metformin: Formulary list price $0.02 per unit (the source does not state the unit; exact figure $0.0247). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02257726)

Source record
DIN 02257726: Teva-Metformin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002008; group id 750; item number 1837; lccId None; manufacturer id TEV Source form: Tab; strength: 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0247; ministry $0.0247 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02257726 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74296
Interchangeable products
Apo-Metformin · DIN 02167786 · $0.0247 Auro-Metformin · DIN 02438275 · $0.0247 Glucophage · DIN 02099233 · $0.0247 Jamp-Metformin · DIN 02380196 · $0.0247 M-Metformin · DIN 02547767 · $0.0247 Mar-Metformin · DIN 02378620 · $0.0247 Metformin · DIN 02353377 · $0.0247 Metformin FC · DIN 02385341 · $0.0247 Mint-Metformin · DIN 02388766 · $0.0247 NRA-Metformin · DIN 02536439 · $0.0247 Novo-Metformin · DIN 02045710 · $0.0247 PMS-Metformin · DIN 02223562 · $0.0247 PMSC-Metformin · DIN 02520303 · $0.0247 PRZ-Metformin · DIN 02531895 · $0.0247 Ran-Metformin · DIN 02269031 · $0.0247 Ratio-Metformin · DIN 02242974 · $0.0247 Sandoz Metformin FC · DIN 02246820 · $0.0247 Septa-Metformin · DIN 02379767 · $0.0247
Shortage status: shortage reported ended May 5, 2026 (report last updated May 5, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02257726
Shortage record checked October 6, 2026

Apo-Metformin ER · DIN 02305062 · 500 mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Apo-Metformin ER · DIN 02305062 Manufacturer: Apotex Inc.; listing date 2010-06-14 Health Canada: Marketed since 2023-06-30 · brand APO-METFORMIN ER · ATC A10BA02 METFORMIN · form Tablet (extended-release) · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02305062)

Source record
DIN 02305062: Apo-Metformin ER Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 682002035; group id 750; item number 1835; lccId None; manufacturer id APX Source form: ER Tab; strength: 500mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.6584; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02305062 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79043
Interchangeable products
Glumetza · DIN 02268493 · not recorded Mar-Metformin XR · DIN 02550504 · not recorded Metformin ER · DIN 02558785 · not recorded Mint-Metformin XR · DIN 02547309 · not recorded Taro-Metformin XR · DIN 02552027 · not recorded
Shortage status: resolved shortage (ended July 25, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02305062
Shortage record checked October 6, 2026

Glumetza · DIN 02268493 · 500 mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Glumetza · DIN 02268493 Manufacturer: Biovail Pharmaceuticals Canada; listing date 2010-06-14 Health Canada: Marketed since 2020-12-22 · brand GLUMETZA · ATC A10BA02 METFORMIN · form Tablet (extended-release) · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG · company Bausch health, canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Glumetza: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02268493)

Source record
DIN 02268493: Glumetza Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 682002035; group id 750; item number 1835; lccId None; manufacturer id BIO Source form: ER Tab; strength: 500mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02268493 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75387
Interchangeable products
Apo-Metformin ER · DIN 02305062 · not recorded Mar-Metformin XR · DIN 02550504 · not recorded Metformin ER · DIN 02558785 · not recorded Mint-Metformin XR · DIN 02547309 · not recorded Taro-Metformin XR · DIN 02552027 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02268493
Shortage record checked October 6, 2026

Mar-Metformin XR · DIN 02550504 · 500 mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Mar-Metformin XR · DIN 02550504 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2024-11-29 Health Canada: Marketed since 2024-10-21 · brand MAR-METFORMIN XR · ATC A10BA02 METFORMIN · form Tablet (extended-release) · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02550504)

Source record
DIN 02550504: Mar-Metformin XR Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 682002035; group id 750; item number 1835; lccId None; manufacturer id MAR Source form: ER Tab; strength: 500mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.6584; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02550504 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103931
Interchangeable products
Apo-Metformin ER · DIN 02305062 · not recorded Glumetza · DIN 02268493 · not recorded Metformin ER · DIN 02558785 · not recorded Mint-Metformin XR · DIN 02547309 · not recorded Taro-Metformin XR · DIN 02552027 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02550504
Shortage record checked October 6, 2026

Metformin ER · DIN 02558785 · 500 mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Metformin ER · DIN 02558785 Manufacturer: Sanis Health Inc.; listing date 2026-01-30 Health Canada: Marketed since 2026-01-08 · brand METFORMIN ER · ATC A10BA02 METFORMIN · form Tablet (extended-release) · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02558785)

Source record
DIN 02558785: Metformin ER Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 682002035; group id 750; item number 1835; lccId None; manufacturer id SAI Source form: ER Tab; strength: 500mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.6584; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02558785 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106200
Interchangeable products
Apo-Metformin ER · DIN 02305062 · not recorded Glumetza · DIN 02268493 · not recorded Mar-Metformin XR · DIN 02550504 · not recorded Mint-Metformin XR · DIN 02547309 · not recorded Taro-Metformin XR · DIN 02552027 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02558785
Shortage record checked October 6, 2026

Mint-Metformin XR · DIN 02547309 · 500 mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Mint-Metformin XR · DIN 02547309 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2024-09-27 Health Canada: Marketed since 2024-10-02 · brand MINT-METFORMIN XR · ATC A10BA02 METFORMIN · form Tablet (extended-release) · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02547309)

Source record
DIN 02547309: Mint-Metformin XR Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 682002035; group id 750; item number 1835; lccId None; manufacturer id MIN Source form: ER Tab; strength: 500mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.6584; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02547309 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103593
Interchangeable products
Apo-Metformin ER · DIN 02305062 · not recorded Glumetza · DIN 02268493 · not recorded Mar-Metformin XR · DIN 02550504 · not recorded Metformin ER · DIN 02558785 · not recorded Taro-Metformin XR · DIN 02552027 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02547309
Shortage record checked October 6, 2026

Taro-Metformin XR · DIN 02552027 · 500 mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Taro-Metformin XR · DIN 02552027 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2025-07-31 Health Canada: Marketed since 2025-10-15 · brand TARO-METFORMIN XR · ATC A10BA02 METFORMIN · form Tablet (extended-release) · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG · company Taro pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02552027)

Source record
DIN 02552027: Taro-Metformin XR Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 682002035; group id 750; item number 1835; lccId None; manufacturer id TAR Source form: ER Tab; strength: 500mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.6584; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02552027 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104072
Interchangeable products
Apo-Metformin ER · DIN 02305062 · not recorded Glumetza · DIN 02268493 · not recorded Mar-Metformin XR · DIN 02550504 · not recorded Metformin ER · DIN 02558785 · not recorded Mint-Metformin XR · DIN 02547309 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02552027
Shortage record checked October 6, 2026

Auro-Metformin · DIN 02438283 · 850 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Auro-Metformin · DIN 02438283 Manufacturer: Auro Pharma Inc.; listing date 2015-08-26 Health Canada: Marketed since 2017-02-22 · brand AURO-METFORMIN · ATC A10BA02 METFORMIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 850 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02438283)

Source record
DIN 02438283: Auro-Metformin Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 682002022; group id 750; item number 1838; lccId None; manufacturer id AUR Source form: Tab; strength: 850mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.2090; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02438283 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92265
Interchangeable products
Apo-Metformin · DIN 02229785 · not recorded Ecl-Metformin · DIN 02421836 · not recorded Glucophage · DIN 02162849 · not recorded Jamp-Metformin · DIN 02380218 · not recorded Jamp-Metformin Blackberry · DIN 02380730 · not recorded M-Metformin · DIN 02547775 · not recorded Mar-Metformin · DIN 02378639 · not recorded Metformin · DIN 02353385 · not recorded Metformin FC · DIN 02385368 · not recorded Mint-Metformin · DIN 02388774 · not recorded NRA-Metformin · DIN 02536447 · not recorded PMS-Metformin · DIN 02242589 · not recorded PMSC-Metformin · DIN 02520311 · not recorded PRZ-Metformin · DIN 02531909 · not recorded Ran-Metformin · DIN 02269058 · not recorded Ratio-Metformin · DIN 02242931 · not recorded Sandoz Metformin FC · DIN 02246821 · not recorded Teva-Metformin · DIN 02257734 · not recorded
Shortage status: resolved shortage (ended April 29, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02438283
Shortage record checked October 6, 2026

Jamp-Metformin · DIN 02380218 · 850 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Jamp-Metformin · DIN 02380218 Manufacturer: Jamp Pharma Corporation; listing date 2012-08-27 Health Canada: Marketed since 2019-09-24 · brand JAMP METFORMIN · ATC A10BA02 METFORMIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 850 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02380218)

Source record
DIN 02380218: Jamp-Metformin Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 682002022; group id 750; item number 1838; lccId None; manufacturer id JPC Source form: Tab; strength: 850mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.2090; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02380218 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86603
Interchangeable products
Apo-Metformin · DIN 02229785 · not recorded Auro-Metformin · DIN 02438283 · not recorded Ecl-Metformin · DIN 02421836 · not recorded Glucophage · DIN 02162849 · not recorded Jamp-Metformin Blackberry · DIN 02380730 · not recorded M-Metformin · DIN 02547775 · not recorded Mar-Metformin · DIN 02378639 · not recorded Metformin · DIN 02353385 · not recorded Metformin FC · DIN 02385368 · not recorded Mint-Metformin · DIN 02388774 · not recorded NRA-Metformin · DIN 02536447 · not recorded PMS-Metformin · DIN 02242589 · not recorded PMSC-Metformin · DIN 02520311 · not recorded PRZ-Metformin · DIN 02531909 · not recorded Ran-Metformin · DIN 02269058 · not recorded Ratio-Metformin · DIN 02242931 · not recorded Sandoz Metformin FC · DIN 02246821 · not recorded Teva-Metformin · DIN 02257734 · not recorded
Shortage status: resolved shortage (ended May 30, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02380218
Shortage record checked October 6, 2026

M-Metformin · DIN 02547775 · 850 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
M-Metformin · DIN 02547775 Manufacturer: Mantra Pharma Inc.; listing date 2025-01-31 Health Canada: Marketed since 2024-11-14 · brand M-METFORMIN · ATC A10BA02 METFORMIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 850 MG · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02547775)

Source record
DIN 02547775: M-Metformin Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 682002022; group id 750; item number 1838; lccId None; manufacturer id MAT Source form: Tab; strength: 850mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.2090; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02547775 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103670
Interchangeable products
Apo-Metformin · DIN 02229785 · not recorded Auro-Metformin · DIN 02438283 · not recorded Ecl-Metformin · DIN 02421836 · not recorded Glucophage · DIN 02162849 · not recorded Jamp-Metformin · DIN 02380218 · not recorded Jamp-Metformin Blackberry · DIN 02380730 · not recorded Mar-Metformin · DIN 02378639 · not recorded Metformin · DIN 02353385 · not recorded Metformin FC · DIN 02385368 · not recorded Mint-Metformin · DIN 02388774 · not recorded NRA-Metformin · DIN 02536447 · not recorded PMS-Metformin · DIN 02242589 · not recorded PMSC-Metformin · DIN 02520311 · not recorded PRZ-Metformin · DIN 02531909 · not recorded Ran-Metformin · DIN 02269058 · not recorded Ratio-Metformin · DIN 02242931 · not recorded Sandoz Metformin FC · DIN 02246821 · not recorded Teva-Metformin · DIN 02257734 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02547775
Shortage record checked October 6, 2026

Mar-Metformin · DIN 02378639 · 850 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Mar-Metformin · DIN 02378639 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2012-06-26 Health Canada: Marketed since 2023-06-26 · brand MAR-METFORMIN · ATC A10BA02 METFORMIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 850 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02378639)

Source record
DIN 02378639: Mar-Metformin Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 682002022; group id 750; item number 1838; lccId None; manufacturer id MAR Source form: Tab; strength: 850mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.2090; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02378639 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86442
Interchangeable products
Apo-Metformin · DIN 02229785 · not recorded Auro-Metformin · DIN 02438283 · not recorded Ecl-Metformin · DIN 02421836 · not recorded Glucophage · DIN 02162849 · not recorded Jamp-Metformin · DIN 02380218 · not recorded Jamp-Metformin Blackberry · DIN 02380730 · not recorded M-Metformin · DIN 02547775 · not recorded Metformin · DIN 02353385 · not recorded Metformin FC · DIN 02385368 · not recorded Mint-Metformin · DIN 02388774 · not recorded NRA-Metformin · DIN 02536447 · not recorded PMS-Metformin · DIN 02242589 · not recorded PMSC-Metformin · DIN 02520311 · not recorded PRZ-Metformin · DIN 02531909 · not recorded Ran-Metformin · DIN 02269058 · not recorded Ratio-Metformin · DIN 02242931 · not recorded Sandoz Metformin FC · DIN 02246821 · not recorded Teva-Metformin · DIN 02257734 · not recorded
Shortage status: discontinued (March 13, 2017, reported by MARCAN PHARMACEUTICALS INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02378639
Shortage record checked October 6, 2026

Metformin · DIN 02353385 · 850 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Metformin · DIN 02353385 Manufacturer: Sanis Health Inc.; listing date 2011-08-04 Health Canada: Marketed since 2019-05-30 · brand METFORMIN · ATC A10BA02 METFORMIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 850 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02353385)

Source record
DIN 02353385: Metformin Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 682002022; group id 750; item number 1838; lccId None; manufacturer id SAI Source form: Tab; strength: 850mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.2090; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02353385 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83858
Interchangeable products
Apo-Metformin · DIN 02229785 · not recorded Auro-Metformin · DIN 02438283 · not recorded Ecl-Metformin · DIN 02421836 · not recorded Glucophage · DIN 02162849 · not recorded Jamp-Metformin · DIN 02380218 · not recorded Jamp-Metformin Blackberry · DIN 02380730 · not recorded M-Metformin · DIN 02547775 · not recorded Mar-Metformin · DIN 02378639 · not recorded Metformin FC · DIN 02385368 · not recorded Mint-Metformin · DIN 02388774 · not recorded NRA-Metformin · DIN 02536447 · not recorded PMS-Metformin · DIN 02242589 · not recorded PMSC-Metformin · DIN 02520311 · not recorded PRZ-Metformin · DIN 02531909 · not recorded Ran-Metformin · DIN 02269058 · not recorded Ratio-Metformin · DIN 02242931 · not recorded Sandoz Metformin FC · DIN 02246821 · not recorded Teva-Metformin · DIN 02257734 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02353385
Shortage record checked October 6, 2026

Metformin FC · DIN 02385368 · 850 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Metformin FC · DIN 02385368 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-11-30 Health Canada: Marketed since 2026-05-20 · brand METFORMIN · ATC A10BA02 METFORMIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 850 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02385368)

Source record
DIN 02385368: Metformin FC Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 682002022; group id 750; item number 1838; lccId None; manufacturer id SIV Source form: Tab; strength: 850mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.2090; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02385368 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87099
Interchangeable products
Apo-Metformin · DIN 02229785 · not recorded Auro-Metformin · DIN 02438283 · not recorded Ecl-Metformin · DIN 02421836 · not recorded Glucophage · DIN 02162849 · not recorded Jamp-Metformin · DIN 02380218 · not recorded Jamp-Metformin Blackberry · DIN 02380730 · not recorded M-Metformin · DIN 02547775 · not recorded Mar-Metformin · DIN 02378639 · not recorded Metformin · DIN 02353385 · not recorded Mint-Metformin · DIN 02388774 · not recorded NRA-Metformin · DIN 02536447 · not recorded PMS-Metformin · DIN 02242589 · not recorded PMSC-Metformin · DIN 02520311 · not recorded PRZ-Metformin · DIN 02531909 · not recorded Ran-Metformin · DIN 02269058 · not recorded Ratio-Metformin · DIN 02242931 · not recorded Sandoz Metformin FC · DIN 02246821 · not recorded Teva-Metformin · DIN 02257734 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02385368
Shortage record checked October 6, 2026

Other products in the same Health Canada class (A10B): coverage varies; not interchangeable

  • Canagliflozin (Invokana): general benefit
  • Dapagliflozin (Forxiga): general benefit
  • Dapagliflozin + metformin (Xigduo): general benefit
  • Empagliflozin (Jardiance): general benefit
  • Empagliflozin + metformin (Synjardy): general benefit
  • Gliclazide (Diamicron MR): general benefit, not a benefit

11 more in the class list below

Other drugs in the same formulary class (68:20:02 Oral Anti-Diabetic Agents) and how they are covered

Matched class: 68:20:02 Oral Anti-Diabetic Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: CANAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN & METFORMIN, EMPAGLIFLOZIN, EMPAGLIFLOZIN & METFORMIN, LINAGLIPTIN, LINAGLIPTIN & METFORMIN, SAXAGLIPTIN, SAXAGLIPTIN & METFORMIN, SITAGLIPTIN Some products covered without a code (check the product listing): GLICLAZIDE, GLYBURIDE 68:20:02 Oral Anti-Diabetic Agents

CANAGLIFLOZIN

· 8 products · General benefit · strengths: 100mg, 300mg · Tab

DAPAGLIFLOZIN

· 22 products · General benefit · strengths: 5mg, 10mg · Tab

DAPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 850mg · Tab

EMPAGLIFLOZIN

· 2 products · General benefit · strengths: 10mg, 25mg · Tab

EMPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 500mg, 5mg & 850mg, 12.5mg & 1000mg, 12.5mg & 500mg, 12.5mg & 850mg · Tab

GLICLAZIDE

· 19 products · General benefit (18), Listed, not a benefit (1) · strengths: 60mg, 30mg, 80mg · ER Tab, SR Tab, Tab

GLYBURIDE

· 8 products · General benefit (6), Listed, not a benefit (2) · strengths: 2.5mg, 5mg · Tab

LINAGLIPTIN

· 1 products · General benefit · strengths: 5mg · Tab

LINAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab

SAXAGLIPTIN

· 6 products · General benefit · strengths: 2.5mg, 5mg · Tab

SAXAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab

SITAGLIPTIN

· 48 products · General benefit · strengths: 25mg, 50mg, 100mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:20:02 and 5 more
Full class listing Related classes: 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications GLUCOPHAGE® (metformin HCl) is indicated for: • the improvement of glycemic control in adult patients with responsive, stable, mild, non- ketosis prone, type 2 diabetes mellitus as an adjunct to proper dietary management, exercise, and weight reduction, or when insulin therapy is not appropriate. • use as monotherapy or in combination with other antidiabetic agents. 1.1. Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see 7. Warnings and Precautions, 7.1.3. Special Populations, Pediatrics). 1.2. Geriatrics (≥ 65 years of age): Controlled clinical studies of GLUCOPHAGE did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients. GLUCOPHAGE is substantially excreted by the kidney and because the risk of serious adverse reactions to the drug is greater in patients with impaired renal function, GLUCOPHAGE should only be used in patients with normal renal function (see 2. Contraindications and 7. Warnings and Precautions, Renal). Because aging is associated with reduced renal funct… https://pdf.hres.ca/dpd_pm/00084167.PDF PM date: 2026-04-07 Source product: GLUCOPHAGE; DIN 02099233; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS • JANUMET® (sitagliptin/metformin hydrochloride) and JANUMET® XR (sitagliptin/metformin hydrochloride extended-release) are indicated for use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus inadequately controlled on metformin or in patients already being treated with the combination of sitagliptin and metformin. • Add-on combination: JANUMET® and JANUMET® XR are indicated for use as a triple combination therapy in adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with: o . sulfonylurea, o . premixed or long/intermediate acting insulin o . pioglitazone when the existing dual therapy with metformin, along with diet and exercise, does not provide adequate glycemic control (see 14 CLINICAL TRIALS). 1.1 Pediatrics • Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of JANUMET® and JANUMET® XR in pediatric patients… https://pdf.hres.ca/dpd_pm/00074655.PDF PM date: FEB 20, 2024 Source product: JANUMET; DIN 02333856; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Mar-Metformin · DIN 02378620 Shortage status: discontinued (2017-11-30, reported by MARCAN PHARMACEUTICALS INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02378620

Check this DIN again

Sandoz Metformin FC · DIN 02246820 Shortage status: shortage reported ended 2026-10-05 (report last updated 2026-10-05); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246820

Check this DIN again

Teva-Metformin · DIN 02257726 Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02257726

Check this DIN again

Mar-Metformin · DIN 02378639 Shortage status: discontinued (2017-03-13, reported by MARCAN PHARMACEUTICALS INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02378639

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Apo-Metformin ER, Glumetza, Mar-Metformin XR, Metformin ER, Mint-Metformin XR, Taro-Metformin XR, Auro-Metformin, Jamp-Metformin, M-Metformin, Mar-Metformin, Metformin, Metformin FC: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026